PMID- 1464468
OWN - NLM
STAT- MEDLINE
DCOM- 19930115
LR  - 20190907
IS  - 0192-0561 (Print)
IS  - 0192-0561 (Linking)
VI  - 14
IP  - 8
DP  - 1992 Nov
TI  - Endogenous production of tumor necrosis factor in normal mice orally treated with 
      Deodan--a preparation from Lactobacillus bulgaricus "LB51".
PG  - 1355-62
AB  - The ability of orally administered Deodan, a product from the cell wall of 
      Lactobacillus bulgaricus strain "I. Bogdanov patent strain tumoronecroticance 
      B51" ATCC #21815, shortly called "LB51", to induce endogenous tumor necrosis 
      factor-alpha (TNF alpha) production in normal mice was evaluated. The priming and 
      triggering activities of the preparation were investigated in combination with 
      lipopolysaccharide (LPS) and live BCG vaccine. Deodan was applied at a dose of 
      150 mg/kg and various treatment schedules were employed. The serum levels of TNF 
      alpha in treated mice were quantified by ELISA. Oral administration of Deodan at 
      a dose of 150 mg/kg for 1, 3, 10 or 20 consecutive days only enhanced serum TNF 
      alpha levels in treated mice. Maximal TNF alpha levels were reached 6 h after the 
      last application of Deodan. Deodan was effective in priming TNF alpha in mice 
      triggered intravenously (i.v.) with LPS. Deodan triggered the production of TNF 
      alpha in BCG-primed mice. The preparation, however, was not an effective trigger 
      of mice primed intradermally (i.d.) with 1 microgram/mouse LPS. These findings 
      suggest that Deodan is both a primer and trigger of endogenous TNF alpha. The 
      advantages of treatment of neoplastic disease with agents which induce endogenous 
      TNF alpha is discussed.
FAU - Davidkova, G
AU  - Davidkova G
AD  - Institute for State Control of Drugs, Sofia, Bulgaria.
FAU - Popova, P
AU  - Popova P
FAU - Guencheva, G
AU  - Guencheva G
FAU - Bogdanov, A
AU  - Bogdanov A
FAU - Pacelli, E
AU  - Pacelli E
FAU - Auteri, A
AU  - Auteri A
FAU - Mincheva, V
AU  - Mincheva V
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Immunopharmacol
JT  - International journal of immunopharmacology
JID - 7904799
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Bacterial Proteins)
RN  - 0 (Glycopeptides)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Administration, Oral
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Bacterial Proteins/*pharmacology
MH  - Cell Wall/chemistry
MH  - Female
MH  - Glycopeptides/*pharmacology
MH  - Hematopoiesis/drug effects
MH  - Lactobacillus/*chemistry
MH  - Lipopolysaccharides
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Tumor Necrosis Factor-alpha/*biosynthesis
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
AID - 0192-0561(92)90006-7 [pii]
AID - 10.1016/0192-0561(92)90006-7 [doi]
PST - ppublish
SO  - Int J Immunopharmacol. 1992 Nov;14(8):1355-62. doi: 10.1016/0192-0561(92)90006-7.